FDA Approves Retevmo for RET-Positive Pediatric Cancers
The Food and Drug Administration (FDA) granted an accelerated approval to Retevmo (selpercatinib) for the children aged two and older with one of the following diseases [...] Of note, this is the first targeted drug to be FDA approved for patients under the age of 12 who have RET alterations. The agent was approved in 2020 for certain patients over the age of 12.
Comentarios